jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Drugs Of Abuse: 9 Drugs

Blood
image

Report in 48Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Rapid urine/blood screening panels.

₹5,624₹8,034

30% OFF

Drugs Of Abuse: 9 Drugs

  • Why is it done?
    • Detects the presence of nine common drugs of abuse in urine or blood samples
    • Typically screens for: Amphetamines, Cocaine, Marijuana (THC), Opioids, Phencyclidine (PCP), Benzodiazepines, Barbiturates, Methadone, and Propoxyphene
    • Ordered for workplace drug screening programs and pre-employment testing
    • Used in clinical settings to monitor patients with substance abuse disorders or compliance with treatment
    • Performed during emergency department evaluations when drug intoxication is suspected
    • May be required as part of legal proceedings, probation monitoring, or pain management contracts
    • Assists in identifying substance abuse in patients presenting with unexplained psychiatric or medical symptoms
  • Normal Range
    • Normal/Negative Result: No detectable levels of any of the nine drugs; typically expressed as "negative" or "<cutoff level" for each substance
    • Cutoff Levels (typical thresholds): Amphetamines: 500 ng/mL (urine), Cocaine: 150 ng/mL (urine), THC: 50 ng/mL (urine), Opioids: 300 ng/mL (urine), PCP: 25 ng/mL (urine), Benzodiazepines: 200 ng/mL (urine), Barbiturates: 200 ng/mL (urine), Methadone: 300 ng/mL (urine), Propoxyphene: 300 ng/mL (urine)
    • Units of Measurement: Nanograms per milliliter (ng/mL) for urine samples; micrograms per liter (μg/L) or ng/mL for blood samples
    • Positive Result: Presence of one or more drugs above the established cutoff threshold; indicates recent use of that substance
    • Interpretation: Negative = No drugs detected; Positive = Drug detected above cutoff level; Borderline/Inconclusive = Levels near cutoff requiring confirmation with more specific testing (GC-MS)
  • Interpretation
    • Negative Result: Indicates no drugs of abuse above cutoff levels detected; patient is unlikely to have used these substances recently; considered "normal" in most contexts
    • Positive Result: Confirms presence of one or more drugs above detection threshold; does not quantify amount of drug present or determine time of use
    • Single vs. Multiple Positives: Detection of single drug may indicate isolated use; multiple positive results suggest polysubstance use or ongoing abuse patterns
    • Factors Affecting Results: Window of detection varies by substance (THC: 2-30 days; cocaine: 2-4 days; opioids: 1-3 days); urine concentration affects detection sensitivity; certain foods, medications, or over-the-counter products may cause false positives
    • False Positives: May occur with certain medications (cold medicines for amphetamines, poppy seeds for opioids); require confirmation with gas chromatography-mass spectrometry (GC-MS)
    • False Negatives: Possible if use occurred before detection window; improper sample collection or storage; diluted samples; or use of substances not included in the 9-drug panel
    • Clinical Significance: Positive results indicate substance exposure but do not prove impairment, addiction, or timing of use; all positive screening results should be confirmed with confirmatory testing
  • Associated Organs
    • Primary Organ Systems: Central nervous system (CNS), affecting brain function, behavior, and cognition; Cardiovascular system (heart and blood vessels); Respiratory system (lungs); Hepatic system (liver)
    • Conditions Associated with Positive Results: Substance use disorder, drug addiction, acute intoxication, drug dependency syndrome, withdrawal syndromes
    • Neurological Effects: Altered consciousness, seizures, psychosis, anxiety, paranoia, hallucinations, tremors, behavioral changes, impaired judgment
    • Cardiovascular Complications: Tachycardia (elevated heart rate), hypertension, arrhythmias, myocardial infarction (heart attack), stroke, cardiomyopathy
    • Respiratory Issues: Acute respiratory depression, hypoxia, aspiration risk, pulmonary edema, chronic obstructive pulmonary disease (COPD)
    • Hepatic Consequences: Liver disease, cirrhosis, hepatitis (especially with injection drug use), impaired drug metabolism
    • Renal System: Acute kidney injury, chronic kidney disease, rhabdomyolysis
    • Infectious Complications: HIV, Hepatitis B and C (with injection drug use), endocarditis, sepsis
    • Potential Risks: Overdose and death, overdose from drug combinations with depressants, aspiration during altered consciousness, trauma from accidents while intoxicated
  • Follow-up Tests
    • Confirmatory Testing: Gas Chromatography-Mass Spectrometry (GC-MS) is the gold standard; recommended for all positive screening results to reduce false positives
    • Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): More sensitive confirmatory method; provides quantitative results
    • Extended Drug Panel Testing: If positive for specific substances, may expand panel to include additional related compounds or synthetic drugs
    • Liver Function Tests: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin; assess hepatic damage from drug use
    • Kidney Function Tests: Creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR); evaluate renal function
    • Infectious Disease Screening: HIV antibody test, Hepatitis B and C serology; recommended for patients with injection drug use history
    • Cardiac Evaluation: Electrocardiogram (ECG) and troponin levels if cocaine or stimulant use suspected; assess for arrhythmias or myocardial infarction
    • Complete Blood Count (CBC): Assess for infections, anemia, thrombocytopenia from drug use
    • Toxicology Panel: Additional comprehensive testing for other substances not in the 9-drug screen (synthetic cannabinoids, new psychoactive substances)
    • Psychiatric Evaluation: Assess for co-occurring mental health disorders, substance use disorder severity, treatment planning
    • Repeat Testing: For monitoring compliance with treatment, workplace programs, or legal monitoring; typically performed at specified intervals (weekly, monthly)
    • Monitoring Frequency: In treatment programs, typically every 2-4 weeks initially; in workplace settings per program requirements; for pain management patients, often monthly
  • Fasting Required?
    • Fasting Required: No - Fasting is not required for the Drugs of Abuse: 9 Drugs test
    • Food and Drink: Patients may eat and drink normally before the test; no dietary restrictions apply
    • Medications: Notify healthcare provider of all medications being taken; certain medications may affect test results or be incorrectly flagged (e.g., cold medicines containing pseudoephedrine, herbal supplements)
    • Prescribed Benzodiazepines and Opioids: Inform provider if legitimately prescribed; required for proper interpretation of positive results in clinical context
    • Sample Collection Instructions: For urine tests, provide mid-stream clean-catch specimen; for blood tests, standard venipuncture performed by phlebotomist
    • Testing Conditions: May require directly observed collection in workplace or legal settings to prevent adulteration or substitution
    • Specimen Storage: Urine samples should be refrigerated if not processed immediately; blood samples processed promptly to maintain sample integrity
    • Timing: Can be performed at any time of day; no specific appointment scheduling constraints related to meals or fasting

How our test process works!

customers
customers